West Pharma (WST) Tops Q3 EPS by 6c, Revenues Beat; Reaffirms FY18 EPS Mid-Point Guidance Above Consensus, Offers FY18 Revenue Outlook
Go back to West Pharma (WST) Tops Q3 EPS by 6c, Revenues Beat; Reaffirms FY18 EPS Mid-Point Guidance Above Consensus, Offers FY18 Revenue Outlook| WEST PHARMACEUTICAL SERVICES, Inc. (NYSE: WST) | Delayed: 336.39 +6.68 (2.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $329.71 | 52 Week High | $84.33 | |||
| Open | $328.45 | 52 Week Low | $53.88 | |||
| Day High | $336.50 | P/E | 214.26 | |||
| Day Low | $327.61 | EPS | $1.57 | |||
| Volume | 784,656 | |||||
